Prognosis of body mass index and chemotherapy dose capping in acute myeloid leukaemia

Body Mass Index (BMI) prognosis in acute myeloid leukaemia (AML) is unknown. Capping chemotherapy dose at 2 m2 of body surface area (BSA) is used without any rationale. We assessed whether both of them could be correlated with outcome in 233 AML patients. Thirty three percent were overweight, 10% obese and BSA over 2 m2 was observed in 15%. BMI and BSA > 2 m2 were not associated with OS (p = 0.16; p = 0.39), nor with DFS (p = 0.18; p = 0.42), nor with CR. OS-associated factors were age (p < 0.001), cytogenetic (p = 0.002), FLT3-ITD (p = 0.01). BMI and chemotherapy dose capping are not pejorative factors on intensively treated AML patients.